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In advanced breast cancer, chemotherapeutic agents are detrimental to bone microarchitecture, 
increasing fracture risk. Given 90% of individuals treated for breast cancer with chemotherapy 
survive five-years post-diagnosis, determining effects of chemotherapies on bone is essential. 
Irinotecan is a chemotherapy drug being trialled for breast cancer treatment, however its effect 
on bone structure and turnover is yet to be studied. This study aimed to determine irinotecan’s 
effect on trabecular bone in the femur and tibia of a rat model of breast cancer via micro-CT, 
immunohistochemistry and ELISA analysis. 
Female dark agouti rats were subcutaneously inoculated with breast cancer cells and allocated 
to two groups; vehicle control (n = 8) and irinotecan (175 mg/kg intraperitoneally; n = 8). Five 
days after treatment, bone microarchitecture was assessed in the femur and tibia via ex-vivo 
micro-CT for; trabecular thickness (Tb.Th.), trabecular number (Tb.N.), trabecular spacing 
(Tb.S.), bone volume (BV), and percent bone volume (BV/TV%). Femur and tibia sections 
were then stained with tartrate-resistant acid phosphatase (TRAP) and assessed for osteoclast-
like cells and adipocytes. Serum was analysed for c-terminal telopeptide 1 (CTX-1). 
Femur and tibia microarchitecture showed no significant difference in Tb.Th., Tb.N. Tb.S. BV 
or BV/TV% between groups. Irinotecan increased TRAP-positive osteoclast-like cell number 
on trabecular bone in the tibia compared to vehicle control (p = 0.033). CTX-1 ELISA analysis 
was indeterminate. 
Overall, irinotecan increased the number of osteoclasts on trabecular bone however did not 
cause microarchitectural changes at this time point. Determining when microarchitecture is 
affected requires further investigation.  
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Introduction 
People treated for cancer with systemic anti-cancer therapies, specifically chemotherapy, are 
at an increased risk of experiencing adverse effects to their bone health which may eventuate 
in osteoporosis and higher risk of osteoporotic fracture1, 2. As a result, several studies have been 
conducted on a variety of these chemotherapies to determine the effects on bone post-treatment. 
A notable example is the chemotherapy drug methotrexate (MTX), which has been researched 
in animal models of cancer and shown that undesirable effects to bone health may be a result 
of increased osteoclast (bone resorbing cells) formation and/or activity at trabecular long bone 
sites3-5, such as the femur and tibia. Increased osteoclast activity in this region causing a 
reduction of total bone volume, consequently increases fracture risk6. It has also been suggested 
other chemotherapies, like lapatinib and paclitaxel, which reduce bone volume, can trigger an 
increase in the number of adipocytes in the trabecular region, known as the “bone-fat switch”6. 
This makes determining the extent at which osteoclasts, adipocytes, and total bone health, are 
affected by chemotherapies of great importance. 
 
Of the cancers treated with chemotherapy, breast cancer is the most prevalent cancer in women 
worldwide7 (not including non-melanoma skin cancers). This prevalence also makes breast 
cancer the second leading cause of death in Australian women, with an estimated 19,500 cases 
in 2019 alone8. Advancements in the therapies used to treat breast cancer however have enabled 
90% of those diagnosed with the disease to survive five-years post diagnosis9. It is estimated 
that 70% of total cancer deaths reveal bone loss at autopsy10 and 73% of breast cancers 
metastasise to the bone, which amplifies this effect11, 12. As some breast cancers are oestrogen-
hormone dependent, they are commonly treated with anti-oestrogen therapies such as selective 
oestrogen receptor modulators (SERMs)13. These treatments aim to significantly deplete 
oestrogen levels to eradicate breast cancer or prevent recurrence, which results in negative 
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effects to bone density loss, as bone is also oestrogen dependent4, 14. This occurs as a direct 
result of oestrogens modulatory effect on the osteoclastogenesis pathway15, which causes 
increased osteoclast activity and survival periods16, thus contributing to increased bone 
resorption.  
 
Oestrogen typically has protective qualities on the bone as it is key in the production of bone 
forming osteoblasts, and with the involvement of osteoprotegerin (OPG), inhibition of 
osteoclasts17. Chemotherapy treatments cause cytokines, such as Interleukin 6 (IL-6) and 
Tumour Necrosis Factor-alpha (TNFα), to be increased in both the marrow space and 
trabecular bone, consequently up-regulating osteoclastogenesis15. As bone density is decreased 
by reductions in oestrogen-hormone, like that seen in post-menopausal women, a greater 
reduction in oestrogen by chemotherapies can have a severe negative effect on bone health17. 
Current cancer hormone therapies used in breast cancer, such as tamoxifen and aromatase 
inhibitors, have indicated that treated individuals experience a significant loss of both cortical 
and trabecular bone18. However, some chemotherapies, like MTX, are also oestrogen 
suppressive which contribute to further reductions in bone mineral density19. This provides the 
opportunity to seek alternative chemotherapy treatments, such as irinotecan, which potentially 
produce lower toxicities in bone by having greater selectivity to cancer cells. 
 
Camptothecin, and its derivative irinotecan, are recognised chemotherapy drugs which target 
cancers by conversion into active metabolite SN-3820, 21. As SN-38, cell death is triggered by 
trapping the topoisomerase-1 enzyme (TOP1) on DNA, generating cytotoxic protein-linked 
DNA breakage22, 23. Irinotecan is currently being trialled for use in breast cancer treatment, it 
has shown to be beneficial in the treatment of numerous other cancers, specifically as colon 
and rectal cancer20. However, Irinotecan has several known side effects, many of which relate 
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to gut health, including mucositis and diarrhoea, as well as myelosuppression4, 20. While these 
side effects are common for many chemotherapeutic agents, reduced gastrointestinal tract 
(GIT) health seen in mucositis may have an impact on intestinal flora and calcium absorption 
19, 24. This is of particular importance in the context of bone health due to the high permeability 
that the GIT possesses25. This impact has significant potential to effect bone metabolites as 
reduced pH in the GIT contributes to higher calcium uptake, thus increasing osteoclast 
formation25, 26. However, little is currently known regarding the effects that irinotecan has on 
bone health, whether individually or in combination with other treatments, specifically at the 
trabecular region. Therefore, further study is required to elucidate the effects of irinotecan on 
bone architecture and remodelling.  
 
Given the known effect that chemotherapy treatments’ have on multiple organ systems, 
including bone, the extent at which this occurs is of particular interest. Specifically, that of 
diminished bone health, resulting from irinotecan used in breast cancer treatment is yet to be 
elucidated. This includes the mechanism that suspected bone resorption transpires in the 
trabecular long bone as a result of irinotecan treatment. It is important to address this in the 
context of breast cancer such that the efficacy of irinotecan for its treatment can be assessed. 
This is a result of bone being oestrogen-dependent and reduction in oestrogen, and thus 
increased osteoclast activity, post-survivorship is highly likely4. With increased survivorship, 
the activity of and presence of osteoclasts in the trabecular long bone following irinotecan 
administration, is of particular significance. Should this gap in the knowledge be filled, through 
research of the specific changes that occur in trabecular bone; the opportunity will arise to 
screen for osteoporosis in treated individuals prior to fractures occurring as targeted 
interventions can be developed. In doing so, the burden on both the individual’s and society’s 




It was hypothesised that irinotecan used in the treatment of breast cancer will increase 
osteoclast formation and thus cause a greater extent of trabecular bone loss compared to a 
vehicle control. To test this hypothesis, the primary aim of this study was to determine the 
effect of irinotecan, in a rat model of breast cancer, on resorption of the trabecular long bone 
using the following sub-aims: Investigate bone microarchitecture of femur and tibia using 
micro-computed tomography (micro-CT). This will include assessment of trabecular thickness 
(Tb.Th), trabecular number (Tb.N), trabecular spacing (Tb.Sp), trabecular bone volume (BV), 
and trabecular bone volume and tissue volume fraction (BV/TV%)27. Determine local 
trabecular bone turnover, by assessing the presence of osteoclasts and adipocytes in trabecular 
femur and tibia through histological assessment of tartrate-resistant acid phosphatase (TRAP) 
staining. Assess systemic bone turnover by measuring serum levels of C-terminal telopeptide 





Breast Cancer Rat Model 
Ethics approval was obtained from the University of Adelaide Animal Ethics Committee 
(33965) in compliance with the National Health and Research Council (Australia) Code of 
Practice for Animal Care in Research and Training. Dark agouti rats were housed in a 12 hour 
light/dark cycle and food and water were provided ad libitum. 
 
Sixteen female dark agouti rats aged eight weeks were randomly allocated to two groups (n = 
8 per group): each group was interperitoneally (i.p.) injected with either irinotecan (175 
mg/kg)29 or vehicle control (sorbitol lactic acid buffer, pH 3.4). Breast cancer was inoculated 
by injection of 4 million breast cancer cells into the subcutaneous flank of the female dark 
agouti rats. These cells were given approximately five days to form a tumour, measured daily 
by callipers to determine tumour burden, until it had grown to ~1% body weight. On day one 
of the treatment schedule, rats received a singular i.p. injection of irinotecan or vehicle control. 
Five days following chemotherapy injection, rats were humanely culled by cardiac puncture. 
Left and right femur and tibia as well as serum were collected for subsequent analysis.  
 
Justification of Methods 
A past study investigated the role of MTX on osteoclastogenesis in a rat model, which indicated 
that MTX decreased total bone density through an increase in osteoclast synthesis and bone 
resorption5. This study quantified osteoclasts at the trabecular surface using TRAP staining 
techniques. A similar study investigated the combined and individual effects of 
chemotherapeutic agents lapatinib and paclitaxel6, primarily through micro-CT analysis. It was 
found that the combination treatment in particular, contributed to significant negative impacts 
to bone health seen by reduced bone volume6. Considering trabecular bone has been shown by 
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multiple studies to be an accurate indicator of effects of chemotherapy on overall bone health3-
5, 30, it is an apt target region to analyse pathological bone loss. By using these techniques, as 
well as supplementary experiments and data collection, for the quantification of irinotecan’s 
effect on trabecular long bone in a model of breast cancer, more comprehensive findings should 
be attained. 
 
Micro-computed tomography analysis 
 
Following collection of femur and tibia, bones were fixed in 10% neutral buffered formalin for 
24 hours. Following this, bones were transferred to 1 x PBS for seven days. Bone changes were 
assessed via images obtained at 9 μm/pixel by micro-CT scanner (SkyScan 1276, Bruker, 
Kontich, Belgium)31. Bones were scanned at a source voltage of 85 kV, current 200 μA, 
isotropic pixel size of 9 μm with a 1 mm thick aluminium filter, rotation step of 0.2, frame 
averaging of 2 and a total scan time of approximately 30 minutes. Cross-sectional images of 
the femur and tibia were reconstructed (N-Recon software, Bruker, Kontich, Belgium) and 
saved in bitmap format. The reconstructed images were re-aligned in 3D as per in-situ 
orientation (Dataviewer software, Bruker, Kontich, Belgium). 
 
The region of interest (ROI) was selected, ensuring to include only the metaphyseal region of 
the trabecular bone in the right femur and right tibia (CT Analyser software, Bruker, Figure 
1)32, 33. This allowed for the exclusion of the growth plate, which has a naturally higher density 
of osteoclast and osteoblast turnover34 . For each femur, 450 cross-sections (corresponding to 
a length of 4.61 mm) starting from the base of the femoral head distally down the femoral shaft 
was used for analysis (Figure 1 A-B)35. For each tibia, 400 cross-sections (corresponding to a 
length of 4.10 mm) starting 60 cross-sections distally from the growth plate centre and ending 
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in the tibial shaft were used for analysis (Figure 1 C-D)35. The trabecular region was then 
selected by tracing serial transverse sections for femur and tibia (Figure 1 B & D) to create the 






















Figure 1. Two-dimensional micro-CT images of proximal right femur (A-B) and proximal 
right tibia (C-D). Total ROI represented by solid orange line (A-D). Lengths of ROI used for 
bone analysis are indicated by the blue arrows. Coronal section vertical ROI distance (450 
cross sections, corresponding to 4.6 mm; and 400 cross sections, corresponding to 4.1 mm 
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On the VOI obtained, Tb.Th. (mm), Tb.N. (1/mm), Tb.S. (mm), BV (mm3), and BV/TV (%) 
were quantified in 3D using uniform thresholding (CT Analyser software, Bruker)33. In the 
grey-level histogram of the reconstructed cross-section images a minimum threshold level was 
used for segmentation of bone pixels from non-bone (minimum threshold level 120 to 
maximum 255), leaving air and any remaining soft tissue as background36. 
 
Histological analysis  
Following micro-CT, all femur and tibia were decalcified in 10% Ethylene diaminetetraacetic 
acid (EDTA) and embedded in paraffin wax35. Serial sections of each bone were cut (5 μm) 
and stained with TRAP. TRAP staining is an established method of identifying osteoclasts in 
tissue as osteoclasts and preosteoclasts are TRAP-positive when stained37, 38. TRAP staining 
was performed using the Tatsuo Suda method39. Serial sections were dewaxed using 
histolene/alcohol series steps and rinsed with MilliQ water. The TRAP solution was prepared 
according to previous validated methods37, 38. Each section was subsequently surrounded using 
a PAP pen, TRAP solution was added onto each section and incubated in a water bath at 37°C 
for approximately 45 minutes. Tissues were then washed with MilliQ and counterstained with 
haematoxylin and cover-slipped using Aquamount. 
 
All slides were scanned using NanoZoomer 2.0 at 40x magnification (Hamamatsu Photonics, 
Japan) and analysed through images produced using NDP.View2 software (Hamamatsu 
Photonics). During analysis, osteoclasts were defined as multinucleated TRAP-positive cells, 
determined by red staining. For quantification of these cells, 1-5 1 mm2 boxes were randomly 
placed within the region determined by micro-CT analysis (Figure 1) and cells were counted 
by a blinded observer, through the use of de-identified file names. An average count of 
multinucleated TRAP-positive cells was then calculated as cells/mm2. 
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Adipocytes were also counted, to explore the previously studied “bone-fat switch” seen in 
chemotherapies such as lapatinib and paclitaxel6. This was performed using the same TRAP-
stained slides and 1 mm2 region of interest boxes. Adipocytes were defined as large, vacant 
cells with a defined edge and an average count (cells/mm2) was found. Though, some cells 
showed cellular debris, they were still included as this was likely due to the thickness of slices 
displaying portions of cells sitting above the adipocytes. 
 
C-Terminal Telopeptide ELISA 
C-terminal telopeptide (CTX-1) is an established indicator of bone resorption in systemic rat 
serum by signifying products of osteoclast activity and collagen breakdown28. The collected 
blood from the rats at cull was spun to produce the serum used for analysis. CTX-1 levels were 
assessed in the serum collected from rats using a RatLaps CTX-1 ELISA kit 
(Immunodiagnostics Systems, Nordic) as per the manufacturers instructions40.  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 8 (GraphPad software). Unpaired t-
test was used to determine differences between irinotecan and vehicle control groups effects 
on trabecular bone for each of the measured parameters. All values shown are mean with SEM 





Micro-CT analysis of trabecular bone 
The femoral and tibial VOIs produced through micro-CT analysis indicated no trabecular bone 
differences between irinotecan treated and vehicle control rats at initial viewing of VOIs 
(Figure 2A & 3A). Statistical analysis of irinotecan treatment displayed no significant changes 
to trabecular bone microarchitecture for Tb.Th., Tb.N., Tb.S., BV, and BV/TV% compared to 
the vehicle control in the femur (p > 0.05, Figure 2). In the tibial trabecular bone, irinotecan 
treatment did not significantly differ from the vehicle control in any of the measured bone 






















Figure 2. Effect of vehicle control or irinotecan on bone microarchitecture in proximal 
femoral trabecular region by high resolution micro-CT. Representative three-dimensional 
micro-CT reconstruction of VOI (A). Analysis of treatment effects in trabecular femur by 
Tb.Th. (mm), Tb.N. (1/mm), Tb.S. (mm), BV (mm3), and BV/TV (%) (B-F, respectively). 
Presented as mean ± SEM (n = 8 per group). Unpaired t-test statistical significance at P < 0.05. 
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Figure 3. Effect of vehicle control or irinotecan on bone microarchitecture in proximal 
tibial trabecular region by high resolution micro-CT. Representative three-dimensional 
micro-CT reconstruction of VOI (A). Analysis of treatment effects in trabecular tibia by Tb.Th. 
(mm), Tb.N. (1/mm), Tb.S. (mm), BV (mm3), and BV/TV (%) (B-F, respectively). Presented 
as mean ± SEM (n = 8 per group). Unpaired t-test statistical significance at P < 0.05. 
B C D 
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A 
Vehicle Control (VC) Irinotecan (IR) 1mm 
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Histological assessment of TRAP staining - Osteoclasts 
Histological assessment of TRAP stained femur sections (representative images in Figure 4A) 
indicated that average multinucleated TRAP-positive cell count in irinotecan treated rats did 
not significantly differ from vehicle control rats (Figure 4B). In the tibia, irinotecan treatment 
significantly increased the average number of TRAP-positive multinucleated cells on the bone 
in the trabecular region of interest (69.46 ± 6.31 cells) compared to the vehicle control (51.51 























Figure 4. Assessment of osteoclasts in proximal femur trabecular bone. Representative 
images of femur sections stained with TRAP (indicated by red colouration) with haematoxylin 
counterstaining, 10x and 40x magnification (A). Arrows indicate some multinucleated TRAP-
positive cells. Average TRAP-positive multinucleated cells per mm2 on the bone surface of 
irinotecan and vehicle control groups (B). Presented as mean ± SEM (n = 8 per group). 
Unpaired t-test statistical significance at P < 0.05. 
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Figure 5. Assessment of osteoclasts in proximal tibia trabecular bone. Representative 
images of tibia sections stained with TRAP (indicated by red colouration) with haematoxylin 
counterstaining, 10x and 40x magnification (A). Arrows indicate some multinucleated TRAP-
positive cells. Average TRAP-positive multinucleated cells per mm2 on the bone surface of 
irinotecan and vehicle control groups (B). Presented as mean ± SEM (n = 8 per group). 
Unpaired t-test statistical significance at P < 0.05. 
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Histological assessment of TRAP staining - Adipocytes 
Adipocyte density in the trabecular region tissue of the femur and tibia are represented in 
Figures 6A and 7A. In in the femur of the irinotecan treated rats, there was no significant 
difference in the number of adipocytes per mm2 in the trabecular tissue region (168.9 ± 30.09 
cells) compared to the vehicle control (129.4 ± 16.33 cells) (p > 0.05, Figure 6B). In the tibia, 
there was an no significant difference in the number of adipocytes per mm2 in the trabecular 
tissue region of irinotecan treated rats (89.51.9 ± 19.85 cells) compared to the vehicle control 























Figure 6. Assessment of adipocyte density in proximal femur trabecular bone. 
Representative images of femur sections stained with TRAP with haematoxylin 
counterstaining, 10x and 40x magnification (A). Arrows indicate some adipocytes. Mean 
adipocytes per mm2 in region of interested tissue for irinotecan and vehicle control groups (B). 
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Figure 7. Assessment of adipocyte density in proximal tibia trabecular bone. 
Representative images of tibia sections stained with TRAP with haematoxylin counterstaining, 
10x and 40x magnification (A). Arrows indicate some adipocytes. Mean adipocytes per mm2 
in region of interested tissue for irinotecan and vehicle control groups (B). Presented as mean 
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CTX-1 ELISA analysis of serum 
C-terminal telopeptide (CTX-1) levels were assessed in the serum collected from both 
irinotecan and vehicle control treated rats as a systemic marker of bone resorption. CTX-1 






This study was the first to investigate the relationship between irinotecan and osteoclasts 
contributing to trabecular bone resorption of the proximal femur and tibia. This was done via 
macroscopic assessment of tissue microarchitecture, TRAP staining techniques for local 
analysis of osteoclast-like cell presence and bone adiposity, and serum analysis of CTX-1 bone 
resorption products. The results suggest that trabecular bone resorption is increased by 
irinotecan treatment, though a longer model is likely required to appreciate this at a 
macroscopic level. 
 
Micro-CT assessment of the femur and tibia in Tb.Th., Tb.N., Tb.S., BV, and BV/TV does not 
reflect the hypothesis which suggested that irinotecan would cause a notable reduction in 
trabecular bone density by action of increased osteoclast activity. Rather, each of these 
parameters displayed no significant difference between the irinotecan and vehicle control 
groups. In accordance with prior literature investigating chemotherapy drugs such as MTX, an 
increase in trabecular resorption was expected4, 5. However, this result may not have been 
present in this study as a direct result of only using the one cull time point, at five days post 
administration of irinotecan. This singular cull time was initially implemented based on 
previous irinotecan studies based on gastrointestinal toxicity, which used five days as the 
maximum treatment time41, 42, and may not have provided enough time to appreciate changes 
in bone degradation assessed at a macroscopic level. Previous studies investigating the effects 
of chemotherapy on bone have used multiple cull timepoints ranging up to 14 days post 
treatment4. 
 
It was expected that osteoclastogenesis would have been increased by day five post-irinotecan 
treatment due to the role of nuclear factor-κB (NFκB), TNFα and cytokine IL-6 in this process. 
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Previous studies have indicated that levels of these cytokines are increased in the GIT at as 
little as two hours post irinotecan administration20. This suggests that an increase in osteoclast-
like cells would have been evident in the TRAP assessment at the five day timepoint. Following 
TRAP staining, the average number of TRAP-positive multinucleated cells was only 
significantly increased by irinotecan compared to the vehicle control in the tibia (p = 0.033). 
Unexpectedly, this was not consistent in the femur with the data indicating no significant 
differences to osteoclast presence compared to the vehicle control. Significance in the tibial 
trabecular bone only, may indicate that the tibia possesses a higher susceptibility to developing 
osteoporosis as a result of irinotecan treatment, or at least doing so at a faster rate, than the 
femur, though this would need further investigation to determine whether this is accurate.  
 
As an increase in osteoclasts can be seen in the tibia, this could indicate the beginning of the 
trabecular bone resorption process in this region. The existing correlation of increased 
osteoclast activation on the trabecular bone surface and its subsequent resorption at a 
macroscopic level, indicate that there had not been sufficient time for this resorption to occur 
prior to the cull point. Thus, it is likely that at a later time point, trabecular bone loss could be 
seen in the microarchitecture through micro-CT. This would indicate that there may be a 
potential window of time for intervention and screening between initial treatment and damage 
to the bone itself taking place. This could signify that there is a delayed onset of morphological 
trabecular bone resorption by osteoclasts, shortly after osteoclast recruitment.  
 
The potential window of time between osteoclast recruitment and trabecular bone resorption 
may provide an opportunity to screen individuals treated with irinotecan. This may include the 
use of bisphosphonates which inhibit osteoclastic bone resorption by targeting osteoclast 
precursors43. Bisphophonates are already established as a standard treatment for bone 
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resorption seen in Paget’s disease and osteoporosis44. Because of this, the use of 
bisphosphonates is recognised for reduction in fracture risk, though some adverse effects to the 
gastroesophageal region, such as increased irritation, have been discovered45. More 
importantly, it has been suggested that the bone formed during bisphosphonate may be of 
reduced quality, leading to higher susceptibility to micro-cracks and consequently fracture 
should the drug be used long-term45-47. This would mean that should patients be prescribed 
with bisphosphonates following irinotecan, they would need to be closely monitored to ensure 
that use is short-term and adequate calcium and vitamin D intake is met, to counteract reduced 
bone quality45. 
 
A delayed onset of bone resorption may also explain why there is no significant changes to the 
adipocyte density between irinotecan and vehicle control groups. The noted reciprocal changes 
in the “bone-fat switch” following chemotherapies such as lapatinib and paclitaxel6, and MTX3 
have been attributed to the common precursor of osteoblasts and adipocytes. However, as bone 
has not yet been significantly diminished by action of osteoclasts in irinotecan treated rats, the 
“switch” has not yet occurred. Although this same research into paclitaxel and lapatinib, 
notifies that further studies are required to understand this process. 
 
The CTX-1 ELISA assay was indeterminate in assessing the collected serum. As a competitive 
assay it was expected that expression of CTX-1 would be indicated by a decreasing standard 
curve. However, upon analysis the curve produced by the known standards was extremely 
shallow and there was both little to no detection of CTX-1 presence and differentiation between 
treatment groups. This indicated that the assay was unsuccessful in producing viable data for 
further analysis.  
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Several pathways for future studies exist for research into the irinotecan’s effect on trabecular 
bone in the context of breast cancer. Particularly, a greater range of cull-time points would 
provide the opportunity to more accurately determine whether this treatment will eventuate in 
diminished microarchitecture at trabecular bone sites. Should this be as expected a more 
accurate window of time for screening and intervention could also be established. Further 
research into the effects of irinotecan on bone could also be aided by the implementation of a 
healthy rat group, which does not experience tumour inoculation, to ensure that the effects seen 
are primarily a result of the chemotherapy itself. Furthermore, investigating the effects of 
irinotecan on bone formation may also be desirable to determine the chemotherapy’s effect on 
bone formation, as well as resorption. Finally, determining the mechanism of irinotecan’s 
action could be investigated through gaining a better understanding of cytokine involvement 
in osteoclast resorption such as NFκB, TNFα, and IL-6. 
 
In conclusion, this is the first study to investigate the effects of chemotherapeutic drug 
irinotecan on trabecular long bone in the context of breast cancer. It was found that irinotecan 
treatment significantly increased the density of multinucleated osteoclasts on the trabecular 
bone surface of the tibia. However, this had not yet taken effect on the trabecular 
microarchitecture of this region. Thus, a potential window for screening and treatment may 
exist shortly after irinotecan administration to counteract bone resorption in patients with 
higher susceptibility to bone loss and fracture. Further investigation is required to determine 
where this intervention window lies, as well as to elucidate the mechanism of action by which 
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